PPIDT00002

Drug Information
NameCetuximab
SequenceQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB00002
Typebiotech
IndicationCetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.[L30448] Cetuximab is also indicated for K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI, a chemotherapy combination that includes [leucovorin], [fluorouracil], and [irinotecan]; in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy; or as monotherapy in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.[L30448] Additionally, cetuximab is also indicated for metastatic colorectal cancer that is BRAF V600E mutation-positive (as determined by an FDA-approved test) in combination with [encorafenib] but only after prior therapy.[L39045] Cetuximab is not indicated for the treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown.[L30448]
Dosage Forms
Form Route Strength
Injection Intravenous
5 MG/ML
Injection, solution Intravenous
5 mg/ml
Injection, solution Intravenous; Parenteral
5 MG/ML
Solution Intravenous
2 mg / mL
Solution Intravenous
2 mg/1mL
Solution Intravenous
5.000 mg
Solution Intravenous
5 mg
Solution Intravenous
500000 mg
Injection, solution Intravenous
100 mg/20ml
Injection, solution Intravenous
500 mg/100ml
Solution Intravenous
5 mg/ml
Solution Intravenous
5 mg/1ml
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P00533 EGFR Epidermal growth factor receptor Homo sapiens binder Link
target O75015 FCGR3B Low affinity immunoglobulin gamma Fc region receptor III-B Homo sapiens binder Link
target P02745 C1QA Complement C1q subcomponent subunit A Homo sapiens binder Link
target P02746 C1QB Complement C1q subcomponent subunit B Homo sapiens binder Link
target P02747 C1QC Complement C1q subcomponent subunit C Homo sapiens binder Link
target P08637 FCGR3A Low affinity immunoglobulin gamma Fc region receptor III-A Homo sapiens binder Link
target P12314 FCGR1A High affinity immunoglobulin gamma Fc receptor I Homo sapiens binder Link
target P12318 FCGR2A Low affinity immunoglobulin gamma Fc region receptor II-a Homo sapiens binder Link